29 August 2023 - Valneva today announced that Health Canada has completed screening validation of the Company’s regulatory application for marketing approval of its single shot chikungunya vaccine candidate VLA1553 in persons aged 18 years and above, and has determined that the new drug submission application is sufficiently complete to permit a substantive review. 

Based on Health Canada’s performance standard to process a new drug submission application, the Company believes the regulatory review could be completed by mid 2024.

Read Valneva press release